Pranlukast Market

ID: MRFR/HC/25467-HCR
100 Pages
Rahul Gotadki
Last Updated: April 06, 2026
Pranlukast Market Research Report By Treatment Type (Asthma, Chronic Obstructive Pulmonary Disease (COPD)), By Drug Formulation (Tablets, Suspension, Inhalers), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Dose Strength (75 mg, 150 mg, 300 mg) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Treatment Type (USD Billion)
      1. 4.1.1 Asthma
      2. 4.1.2 Chronic Obstructive Pulmonary Disease (COPD)
    2. 4.2 Healthcare, BY Drug Formulation (USD Billion)
      1. 4.2.1 Tablets
      2. 4.2.2 Suspension
      3. 4.2.3 Inhalers
    3. 4.3 Healthcare, BY Distribution Channel (USD Billion)
      1. 4.3.1 Hospital Pharmacies
      2. 4.3.2 Retail Pharmacies
      3. 4.3.3 Online Pharmacies
    4. 4.4 Healthcare, BY Dose Strength (USD Billion)
      1. 4.4.1 75 mg
      2. 4.4.2 150 mg
      3. 4.4.3 300 mg
    5. 4.5 Healthcare, BY Region (USD Billion)
      1. 4.5.1 North America
        1. 4.5.1.1 US
        2. 4.5.1.2 Canada
      2. 4.5.2 Europe
        1. 4.5.2.1 Germany
        2. 4.5.2.2 UK
        3. 4.5.2.3 France
        4. 4.5.2.4 Russia
        5. 4.5.2.5 Italy
        6. 4.5.2.6 Spain
        7. 4.5.2.7 Rest of Europe
      3. 4.5.3 APAC
        1. 4.5.3.1 China
        2. 4.5.3.2 India
        3. 4.5.3.3 Japan
        4. 4.5.3.4 South Korea
        5. 4.5.3.5 Malaysia
        6. 4.5.3.6 Thailand
        7. 4.5.3.7 Indonesia
        8. 4.5.3.8 Rest of APAC
      4. 4.5.4 South America
        1. 4.5.4.1 Brazil
        2. 4.5.4.2 Mexico
        3. 4.5.4.3 Argentina
        4. 4.5.4.4 Rest of South America
      5. 4.5.5 MEA
        1. 4.5.5.1 GCC Countries
        2. 4.5.5.2 South Africa
        3. 4.5.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Mylan (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Teva Pharmaceuticals (IL)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Cipla (IN)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Sun Pharmaceutical Industries (IN)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Aurobindo Pharma (IN)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Hikma Pharmaceuticals (GB)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Sandoz (CH)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Zydus Cadila (IN)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
    4. 6.4 US MARKET ANALYSIS BY DRUG FORMULATION
    5. 6.5 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    6. 6.6 US MARKET ANALYSIS BY DOSE STRENGTH
    7. 6.7 CANADA MARKET ANALYSIS BY TREATMENT TYPE
    8. 6.8 CANADA MARKET ANALYSIS BY DRUG FORMULATION
    9. 6.9 CANADA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    10. 6.10 CANADA MARKET ANALYSIS BY DOSE STRENGTH
    11. 6.11 EUROPE MARKET ANALYSIS
    12. 6.12 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
    13. 6.13 GERMANY MARKET ANALYSIS BY DRUG FORMULATION
    14. 6.14 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    15. 6.15 GERMANY MARKET ANALYSIS BY DOSE STRENGTH
    16. 6.16 UK MARKET ANALYSIS BY TREATMENT TYPE
    17. 6.17 UK MARKET ANALYSIS BY DRUG FORMULATION
    18. 6.18 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    19. 6.19 UK MARKET ANALYSIS BY DOSE STRENGTH
    20. 6.20 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
    21. 6.21 FRANCE MARKET ANALYSIS BY DRUG FORMULATION
    22. 6.22 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    23. 6.23 FRANCE MARKET ANALYSIS BY DOSE STRENGTH
    24. 6.24 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
    25. 6.25 RUSSIA MARKET ANALYSIS BY DRUG FORMULATION
    26. 6.26 RUSSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    27. 6.27 RUSSIA MARKET ANALYSIS BY DOSE STRENGTH
    28. 6.28 ITALY MARKET ANALYSIS BY TREATMENT TYPE
    29. 6.29 ITALY MARKET ANALYSIS BY DRUG FORMULATION
    30. 6.30 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    31. 6.31 ITALY MARKET ANALYSIS BY DOSE STRENGTH
    32. 6.32 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
    33. 6.33 SPAIN MARKET ANALYSIS BY DRUG FORMULATION
    34. 6.34 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    35. 6.35 SPAIN MARKET ANALYSIS BY DOSE STRENGTH
    36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
    37. 6.37 REST OF EUROPE MARKET ANALYSIS BY DRUG FORMULATION
    38. 6.38 REST OF EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    39. 6.39 REST OF EUROPE MARKET ANALYSIS BY DOSE STRENGTH
    40. 6.40 APAC MARKET ANALYSIS
    41. 6.41 CHINA MARKET ANALYSIS BY TREATMENT TYPE
    42. 6.42 CHINA MARKET ANALYSIS BY DRUG FORMULATION
    43. 6.43 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    44. 6.44 CHINA MARKET ANALYSIS BY DOSE STRENGTH
    45. 6.45 INDIA MARKET ANALYSIS BY TREATMENT TYPE
    46. 6.46 INDIA MARKET ANALYSIS BY DRUG FORMULATION
    47. 6.47 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    48. 6.48 INDIA MARKET ANALYSIS BY DOSE STRENGTH
    49. 6.49 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
    50. 6.50 JAPAN MARKET ANALYSIS BY DRUG FORMULATION
    51. 6.51 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    52. 6.52 JAPAN MARKET ANALYSIS BY DOSE STRENGTH
    53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
    54. 6.54 SOUTH KOREA MARKET ANALYSIS BY DRUG FORMULATION
    55. 6.55 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    56. 6.56 SOUTH KOREA MARKET ANALYSIS BY DOSE STRENGTH
    57. 6.57 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
    58. 6.58 MALAYSIA MARKET ANALYSIS BY DRUG FORMULATION
    59. 6.59 MALAYSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    60. 6.60 MALAYSIA MARKET ANALYSIS BY DOSE STRENGTH
    61. 6.61 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
    62. 6.62 THAILAND MARKET ANALYSIS BY DRUG FORMULATION
    63. 6.63 THAILAND MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    64. 6.64 THAILAND MARKET ANALYSIS BY DOSE STRENGTH
    65. 6.65 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
    66. 6.66 INDONESIA MARKET ANALYSIS BY DRUG FORMULATION
    67. 6.67 INDONESIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    68. 6.68 INDONESIA MARKET ANALYSIS BY DOSE STRENGTH
    69. 6.69 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
    70. 6.70 REST OF APAC MARKET ANALYSIS BY DRUG FORMULATION
    71. 6.71 REST OF APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    72. 6.72 REST OF APAC MARKET ANALYSIS BY DOSE STRENGTH
    73. 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. 6.74 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
    75. 6.75 BRAZIL MARKET ANALYSIS BY DRUG FORMULATION
    76. 6.76 BRAZIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    77. 6.77 BRAZIL MARKET ANALYSIS BY DOSE STRENGTH
    78. 6.78 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
    79. 6.79 MEXICO MARKET ANALYSIS BY DRUG FORMULATION
    80. 6.80 MEXICO MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    81. 6.81 MEXICO MARKET ANALYSIS BY DOSE STRENGTH
    82. 6.82 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
    83. 6.83 ARGENTINA MARKET ANALYSIS BY DRUG FORMULATION
    84. 6.84 ARGENTINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    85. 6.85 ARGENTINA MARKET ANALYSIS BY DOSE STRENGTH
    86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
    87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG FORMULATION
    88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DOSE STRENGTH
    90. 6.90 MEA MARKET ANALYSIS
    91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
    92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DRUG FORMULATION
    93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY DOSE STRENGTH
    95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
    96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DRUG FORMULATION
    97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY DOSE STRENGTH
    99. 6.99 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
    100. 6.100 REST OF MEA MARKET ANALYSIS BY DRUG FORMULATION
    101. 6.101 REST OF MEA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    102. 6.102 REST OF MEA MARKET ANALYSIS BY DOSE STRENGTH
    103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. 6.104 RESEARCH PROCESS OF MRFR
    105. 6.105 DRO ANALYSIS OF HEALTHCARE
    106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. 6.109 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
    110. 6.110 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
    111. 6.111 HEALTHCARE, BY DRUG FORMULATION, 2024 (% SHARE)
    112. 6.112 HEALTHCARE, BY DRUG FORMULATION, 2024 TO 2035 (USD Billion)
    113. 6.113 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    114. 6.114 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
    115. 6.115 HEALTHCARE, BY DOSE STRENGTH, 2024 (% SHARE)
    116. 6.116 HEALTHCARE, BY DOSE STRENGTH, 2024 TO 2035 (USD Billion)
    117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.2.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.3.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.3.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.3.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.4.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.4.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.4.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.5.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.5.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.5.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.6.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.6.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.6.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.7.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.7.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.7.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.8.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.8.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.8.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.9.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.9.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.9.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.10.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.10.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.10.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.11.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.11.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.11.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.12.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.12.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.12.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.13.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.13.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.13.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.14.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.14.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.14.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.15.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.15.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.15.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.16.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.16.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.16.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.17.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.17.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.17.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.18.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.18.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.18.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.19.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.19.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.19.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.20.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.20.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.20.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.21.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.21.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.21.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.22.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.22.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.22.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.23.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.23.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.23.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.24.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.24.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.24.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.25.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.25.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.25.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.26.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.26.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.26.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.27.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.27.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.27.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.28.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.28.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.28.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.29.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.29.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.29.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.30.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
      3. 7.30.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.30.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Pranlukast Market Segmentation

Pranlukast Market By Treatment Type (USD Billion, 2025-2035)

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)

Pranlukast Market By Drug Formulation (USD Billion, 2025-2035)

  • Tablets
  • Suspension
  • Inhalers

Pranlukast Market By Distribution Channel (USD Billion, 2025-2035)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Pranlukast Market By Dose Strength (USD Billion, 2025-2035)

  • 75 mg
  • 150 mg
  • 300 mg